Boston Scientific Corp (BSX)
$90.56 $0.35 (0.39%) 4:38 PM 12/11/24
NYSE | $USD | Medical DevicesStock Data
-
Market Cap
$132.75B -
Day's Range
$90.15 - $90.97 -
Volume
4,409,667 -
52 Week Low / High
$54.86 - $91.93 -
PE Ratio
74.44x -
PEG Ratio
1.63 -
Dividend Frequency
-
- Capital Growth
- Dividend Return to Date
- Dividend Payout year Est.
- Expenses
- Total Return
- Total Return %
- 20
- Strong Buy
- 8
- Buy
- 5
- Hold
- 0
- Sell
- 0
- Strong Sell
- $61.18
- Target Price
Company News
-
Boston Scientific stock down as Needham cuts to Hold on growth concerns — Oct 18th, 2024
Investing.com -- Shares in Boston Scientific (NYSE:BSX) fell more than 1% in premarket trading Friday after analysts at Needham&Co. downgraded the stock to Hold from Buy, citing several concerns about the company's future growth and market competition. The investment firm pointed to an an...
-
Boston Scientific Shares Likely to Gain After FARAWAVE NAV Approval — Oct 21st, 2024
Boston Scientific Corporation BSX has secured FDA approval for its FARAWAVE NAV Ablation Catheter and 510(k) clearance for FARAVIEW Software, offering integrated mapping and pulsed-field ablation (PFA) for treating paroxysmal atrial fibrillation (AF). The technologies streamline workflows ...
-
Slowing Rates Of Return At Boston Scientific (NYSE:BSX) Leave Little Room For Excitement — Oct 21st, 2024
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for? Firstly, we'd want to identify a growing return on capital employed (ROCE) and then alongside that, an ever-increasing base of capital employed. This shows us that it's a c...
-
Slowing Rates Of Return At Boston Scientific (NYSE:BSX) Leave Little Room For Excitement — Oct 21st, 2024
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for? Firstly, we'd want to identify a growing return on capital employed (ROCE) and then alongside that, an ever-increasing base of capital employed. This shows us that it's a c...
-
Boston Scientific Shares Likely to Gain After FARAWAVE NAV Approval — Oct 21st, 2024
Boston Scientific Corporation BSX has secured FDA approval for its FARAWAVE NAV Ablation Catheter and 510(k) clearance for FARAVIEW Software, offering integrated mapping and pulsed-field ablation (PFA) for treating paroxysmal atrial fibrillation (AF). The technologies streamline workflows ...
-
Boston Scientific Shares Likely to Gain After FARAWAVE NAV Approval — Oct 21st, 2024
Boston Scientific Corporation BSX has secured FDA approval for its FARAWAVE NAV Ablation Catheter and 510(k) clearance for FARAVIEW Software, offering integrated mapping and pulsed-field ablation (PFA) for treating paroxysmal atrial fibrillation (AF). The technologies streamline workflows ...
-
Slowing Rates Of Return At Boston Scientific (NYSE:BSX) Leave Little Room For Excitement — Oct 21st, 2024
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for? Firstly, we'd want to identify a growing return on capital employed (ROCE) and then alongside that, an ever-increasing base of capital employed. This shows us that it's a c...
-
Boston Scientific Launches Next Generation of Cardiac Mapping for the FARAPULSE™ Pulsed Field Ablation System — Oct 18th, 2024
New FARAWAVE™ NAV Ablation Catheter and FARAVIEW™ Software combine with OPAL HDx™ Mapping System to provide visualization during pulsed field ablation MARLBOROUGH, Mass., Oct. 18, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Foo...
-
Boston Scientific stock down as Needham cuts to Hold on growth concerns — Oct 18th, 2024
Investing.com -- Shares in Boston Scientific (NYSE:BSX) fell more than 1% in premarket trading Friday after analysts at Needham&Co. downgraded the stock to Hold from Buy, citing several concerns about the company's future growth and market competition. The investment firm pointed to an an...
-
Boston Scientific Shares Likely to Gain After FARAWAVE NAV Approval — Oct 21st, 2024
Boston Scientific Corporation BSX has secured FDA approval for its FARAWAVE NAV Ablation Catheter and 510(k) clearance for FARAVIEW Software, offering integrated mapping and pulsed-field ablation (PFA) for treating paroxysmal atrial fibrillation (AF). The technologies streamline workflows ...
-
Boston Scientific launches next-gen cardiac mapping for FARAPULSE — Oct 19th, 2024
https://www.tipranks.com/news/the-fly/boston-scientific-launches-next-gen-cardiac-mapping-for-farapulse Boston Scientific (BSX) Corporation announced it has received U.S. Food and Drug Administration approval for the navigation-enabled FARAWAVE NAV Ablation Catheter for the treatment of p...
-
Boston Scientific Launches Next Generation of Cardiac Mapping for the FARAPULSE™ Pulsed Field Ablation System — Oct 18th, 2024
New FARAWAVE™ NAV Ablation Catheter and FARAVIEW™ Software combine with OPAL HDx™ Mapping System to provide visualization during pulsed field ablation MARLBOROUGH, Mass., Oct. 18, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Foo...
-
Boston Scientific launches next-gen cardiac mapping for FARAPULSE — Oct 19th, 2024
https://www.tipranks.com/news/the-fly/boston-scientific-launches-next-gen-cardiac-mapping-for-farapulse Boston Scientific (BSX) Corporation announced it has received U.S. Food and Drug Administration approval for the navigation-enabled FARAWAVE NAV Ablation Catheter for the treatment of p...
-
Slowing Rates Of Return At Boston Scientific (NYSE:BSX) Leave Little Room For Excitement — Oct 21st, 2024
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for? Firstly, we'd want to identify a growing return on capital employed (ROCE) and then alongside that, an ever-increasing base of capital employed. This shows us that it's a c...
-
Boston Scientific Launches Next Generation of Cardiac Mapping for the FARAPULSE™ Pulsed Field Ablation System — Oct 18th, 2024
New FARAWAVE™ NAV Ablation Catheter and FARAVIEW™ Software combine with OPAL HDx™ Mapping System to provide visualization during pulsed field ablation MARLBOROUGH, Mass., Oct. 18, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Foo...
-
Boston Scientific launches next-gen cardiac mapping for FARAPULSE — Oct 19th, 2024
https://www.tipranks.com/news/the-fly/boston-scientific-launches-next-gen-cardiac-mapping-for-farapulse Boston Scientific (BSX) Corporation announced it has received U.S. Food and Drug Administration approval for the navigation-enabled FARAWAVE NAV Ablation Catheter for the treatment of p...
-
Boston Scientific Shares Likely to Gain After FARAWAVE NAV Approval — Oct 21st, 2024
Boston Scientific Corporation BSX has secured FDA approval for its FARAWAVE NAV Ablation Catheter and 510(k) clearance for FARAVIEW Software, offering integrated mapping and pulsed-field ablation (PFA) for treating paroxysmal atrial fibrillation (AF). The technologies streamline workflows ...
-
Slowing Rates Of Return At Boston Scientific (NYSE:BSX) Leave Little Room For Excitement — Oct 21st, 2024
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for? Firstly, we'd want to identify a growing return on capital employed (ROCE) and then alongside that, an ever-increasing base of capital employed. This shows us that it's a c...
-
Boston Scientific (BSX) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates — Oct 18th, 2024
The upcoming report from Boston Scientific (BSX) is expected to reveal quarterly earnings of $0.58 per share, indicating an increase of 16% compared to the year-ago period. Analysts forecast revenues of $4.03 billion, representing an increase of 14.4% year over year. Over the past 30 days...
-
Boston Scientific Shares Likely to Gain After FARAWAVE NAV Approval — Oct 21st, 2024
Boston Scientific Corporation BSX has secured FDA approval for its FARAWAVE NAV Ablation Catheter and 510(k) clearance for FARAVIEW Software, offering integrated mapping and pulsed-field ablation (PFA) for treating paroxysmal atrial fibrillation (AF). The technologies streamline workflows ...
-
Boston Scientific Launches Next Generation of Cardiac Mapping for the FARAPULSE™ Pulsed Field Ablation System — Oct 18th, 2024
New FARAWAVE™ NAV Ablation Catheter and FARAVIEW™ Software combine with OPAL HDx™ Mapping System to provide visualization during pulsed field ablation MARLBOROUGH, Mass., Oct. 18, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Foo...
-
Boston Scientific launches next-gen cardiac mapping for FARAPULSE — Oct 19th, 2024
https://www.tipranks.com/news/the-fly/boston-scientific-launches-next-gen-cardiac-mapping-for-farapulse Boston Scientific (BSX) Corporation announced it has received U.S. Food and Drug Administration approval for the navigation-enabled FARAWAVE NAV Ablation Catheter for the treatment of p...
-
Slowing Rates Of Return At Boston Scientific (NYSE:BSX) Leave Little Room For Excitement — Oct 21st, 2024
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for? Firstly, we'd want to identify a growing return on capital employed (ROCE) and then alongside that, an ever-increasing base of capital employed. This shows us that it's a c...
-
Boston Scientific Launches Next Generation of Cardiac Mapping for the FARAPULSE™ Pulsed Field Ablation System — Oct 18th, 2024
New FARAWAVE™ NAV Ablation Catheter and FARAVIEW™ Software combine with OPAL HDx™ Mapping System to provide visualization during pulsed field ablation MARLBOROUGH, Mass., Oct. 18, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Foo...
-
Slowing Rates Of Return At Boston Scientific (NYSE:BSX) Leave Little Room For Excitement — Oct 21st, 2024
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for? Firstly, we'd want to identify a growing return on capital employed (ROCE) and then alongside that, an ever-increasing base of capital employed. This shows us that it's a c...
-
Boston Scientific launches next-gen cardiac mapping for FARAPULSE — Oct 19th, 2024
https://www.tipranks.com/news/the-fly/boston-scientific-launches-next-gen-cardiac-mapping-for-farapulse Boston Scientific (BSX) Corporation announced it has received U.S. Food and Drug Administration approval for the navigation-enabled FARAWAVE NAV Ablation Catheter for the treatment of p...
-
Boston Scientific (BSX) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates — Oct 18th, 2024
The upcoming report from Boston Scientific (BSX) is expected to reveal quarterly earnings of $0.58 per share, indicating an increase of 16% compared to the year-ago period. Analysts forecast revenues of $4.03 billion, representing an increase of 14.4% year over year. Over the past 30 days...
-
Boston Scientific launches next-gen cardiac mapping for FARAPULSE — Oct 19th, 2024
https://www.tipranks.com/news/the-fly/boston-scientific-launches-next-gen-cardiac-mapping-for-farapulse Boston Scientific (BSX) Corporation announced it has received U.S. Food and Drug Administration approval for the navigation-enabled FARAWAVE NAV Ablation Catheter for the treatment of p...
-
Boston Scientific Shares Likely to Gain After FARAWAVE NAV Approval — Oct 21st, 2024
Boston Scientific Corporation BSX has secured FDA approval for its FARAWAVE NAV Ablation Catheter and 510(k) clearance for FARAVIEW Software, offering integrated mapping and pulsed-field ablation (PFA) for treating paroxysmal atrial fibrillation (AF). The technologies streamline workflows ...
-
Boston Scientific (BSX) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates — Oct 18th, 2024
The upcoming report from Boston Scientific (BSX) is expected to reveal quarterly earnings of $0.58 per share, indicating an increase of 16% compared to the year-ago period. Analysts forecast revenues of $4.03 billion, representing an increase of 14.4% year over year. Over the past 30 days...
-
Boston Scientific Launches Next Generation of Cardiac Mapping for the FARAPULSE™ Pulsed Field Ablation System — Oct 18th, 2024
New FARAWAVE™ NAV Ablation Catheter and FARAVIEW™ Software combine with OPAL HDx™ Mapping System to provide visualization during pulsed field ablation MARLBOROUGH, Mass., Oct. 18, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Foo...
-
Boston Scientific Shares Likely to Gain After FARAWAVE NAV Approval — Oct 21st, 2024
Boston Scientific Corporation BSX has secured FDA approval for its FARAWAVE NAV Ablation Catheter and 510(k) clearance for FARAVIEW Software, offering integrated mapping and pulsed-field ablation (PFA) for treating paroxysmal atrial fibrillation (AF). The technologies streamline workflows ...
-
Boston Scientific Shares Likely to Gain After FARAWAVE NAV Approval — Oct 21st, 2024
Boston Scientific Corporation BSX has secured FDA approval for its FARAWAVE NAV Ablation Catheter and 510(k) clearance for FARAVIEW Software, offering integrated mapping and pulsed-field ablation (PFA) for treating paroxysmal atrial fibrillation (AF). The technologies streamline workflows ...
-
Boston Scientific launches next-gen cardiac mapping for FARAPULSE — Oct 19th, 2024
https://www.tipranks.com/news/the-fly/boston-scientific-launches-next-gen-cardiac-mapping-for-farapulse Boston Scientific (BSX) Corporation announced it has received U.S. Food and Drug Administration approval for the navigation-enabled FARAWAVE NAV Ablation Catheter for the treatment of p...
-
Boston Scientific launches next-gen cardiac mapping for FARAPULSE — Oct 19th, 2024
https://www.tipranks.com/news/the-fly/boston-scientific-launches-next-gen-cardiac-mapping-for-farapulse Boston Scientific (BSX) Corporation announced it has received U.S. Food and Drug Administration approval for the navigation-enabled FARAWAVE NAV Ablation Catheter for the treatment of p...
-
Boston Scientific (BSX) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates — Oct 18th, 2024
The upcoming report from Boston Scientific (BSX) is expected to reveal quarterly earnings of $0.58 per share, indicating an increase of 16% compared to the year-ago period. Analysts forecast revenues of $4.03 billion, representing an increase of 14.4% year over year. Over the past 30 days...
-
Boston Scientific Shares Likely to Gain After FARAWAVE NAV Approval — Oct 21st, 2024
Boston Scientific Corporation BSX has secured FDA approval for its FARAWAVE NAV Ablation Catheter and 510(k) clearance for FARAVIEW Software, offering integrated mapping and pulsed-field ablation (PFA) for treating paroxysmal atrial fibrillation (AF). The technologies streamline workflows ...
-
Boston Scientific launches next-gen cardiac mapping for FARAPULSE — Oct 19th, 2024
https://www.tipranks.com/news/the-fly/boston-scientific-launches-next-gen-cardiac-mapping-for-farapulse Boston Scientific (BSX) Corporation announced it has received U.S. Food and Drug Administration approval for the navigation-enabled FARAWAVE NAV Ablation Catheter for the treatment of p...
-
Slowing Rates Of Return At Boston Scientific (NYSE:BSX) Leave Little Room For Excitement — Oct 21st, 2024
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for? Firstly, we'd want to identify a growing return on capital employed (ROCE) and then alongside that, an ever-increasing base of capital employed. This shows us that it's a c...
-
Slowing Rates Of Return At Boston Scientific (NYSE:BSX) Leave Little Room For Excitement — Oct 21st, 2024
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for? Firstly, we'd want to identify a growing return on capital employed (ROCE) and then alongside that, an ever-increasing base of capital employed. This shows us that it's a c...
-
Boston Scientific launches next-gen cardiac mapping for FARAPULSE — Oct 19th, 2024
https://www.tipranks.com/news/the-fly/boston-scientific-launches-next-gen-cardiac-mapping-for-farapulse Boston Scientific (BSX) Corporation announced it has received U.S. Food and Drug Administration approval for the navigation-enabled FARAWAVE NAV Ablation Catheter for the treatment of p...
-
Slowing Rates Of Return At Boston Scientific (NYSE:BSX) Leave Little Room For Excitement — Oct 21st, 2024
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for? Firstly, we'd want to identify a growing return on capital employed (ROCE) and then alongside that, an ever-increasing base of capital employed. This shows us that it's a c...
-
Slowing Rates Of Return At Boston Scientific (NYSE:BSX) Leave Little Room For Excitement — Oct 21st, 2024
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for? Firstly, we'd want to identify a growing return on capital employed (ROCE) and then alongside that, an ever-increasing base of capital employed. This shows us that it's a c...
-
Slowing Rates Of Return At Boston Scientific (NYSE:BSX) Leave Little Room For Excitement — Oct 21st, 2024
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for? Firstly, we'd want to identify a growing return on capital employed (ROCE) and then alongside that, an ever-increasing base of capital employed. This shows us that it's a c...
-
Boston Scientific launches next-gen cardiac mapping for FARAPULSE — Oct 19th, 2024
https://www.tipranks.com/news/the-fly/boston-scientific-launches-next-gen-cardiac-mapping-for-farapulse Boston Scientific (BSX) Corporation announced it has received U.S. Food and Drug Administration approval for the navigation-enabled FARAWAVE NAV Ablation Catheter for the treatment of p...
-
Boston Scientific stock down as Needham cuts to Hold on growth concerns — Oct 18th, 2024
Investing.com -- Shares in Boston Scientific (NYSE:BSX) fell more than 1% in premarket trading Friday after analysts at Needham&Co. downgraded the stock to Hold from Buy, citing several concerns about the company's future growth and market competition. The investment firm pointed to an an...
-
Boston Scientific Shares Likely to Gain After FARAWAVE NAV Approval — Oct 21st, 2024
Boston Scientific Corporation BSX has secured FDA approval for its FARAWAVE NAV Ablation Catheter and 510(k) clearance for FARAVIEW Software, offering integrated mapping and pulsed-field ablation (PFA) for treating paroxysmal atrial fibrillation (AF). The technologies streamline workflows ...
-
Boston Scientific Shares Likely to Gain After FARAWAVE NAV Approval — Oct 21st, 2024
Boston Scientific Corporation BSX has secured FDA approval for its FARAWAVE NAV Ablation Catheter and 510(k) clearance for FARAVIEW Software, offering integrated mapping and pulsed-field ablation (PFA) for treating paroxysmal atrial fibrillation (AF). The technologies streamline workflows ...
-
Boston Scientific Shares Likely to Gain After FARAWAVE NAV Approval — Oct 21st, 2024
Boston Scientific Corporation BSX has secured FDA approval for its FARAWAVE NAV Ablation Catheter and 510(k) clearance for FARAVIEW Software, offering integrated mapping and pulsed-field ablation (PFA) for treating paroxysmal atrial fibrillation (AF). The technologies streamline workflows ...
-
Slowing Rates Of Return At Boston Scientific (NYSE:BSX) Leave Little Room For Excitement — Oct 21st, 2024
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for? Firstly, we'd want to identify a growing return on capital employed (ROCE) and then alongside that, an ever-increasing base of capital employed. This shows us that it's a c...
Portfolio
Comprised of 1 portfolios